Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement

Table 1 Characteristics of the 35 patients

	n (%)
Male sex	32 (91.4)
Median age (range, yr)	67 (47-86)
Lugano staging system
Stage I	1
Stage II-1	1
Stage II-2	4
Stage IV	29
Involved site of gastrointestinal tract
Esophagus	2/35 (5.7)
Stomach	26/35 (74.3)
Duodenum	12/35 (34.3)
Ileum	10/21 (47.6)
Cecum	3/21 (14.3)
Colon	12/21 (57.1)
Rectum	10/21 (47.6)
Mitotic rate (Ki-67 index) (n = 19)
Low mitotic rate	9
High mitotic rate	10
MIPI score (n = 31)
Average score (range)	6.01 (5.31-6.85)
Low risk	6
Intermediate risk	15
High risk	10

MIPI: Mantle cell lymphoma international prognostic index.

Table 2 Gross findings of the gastrointestinal tract

	Esophagus (n = 2)	Stomach (n = 26)	Intestines (n = 22)
Protruded	1	6	4
Fold thickening	-	6	-
MLP	-	-	17
Ulcerative	-	6	-
Superficial	1	7	1
Mixed	-	1	-

The intestines include the duodenum, ileum, cecum, colon, and rectum. MLP: Multiple lymphomatous polyposis.

Table 3 Prognostic relevance of overall survival according to the univariate Cox regression

Prognostic factor	Comparison	n	RR	95% LCL	95% UCL	P
Age (yr)	≥ 60 vs < 60	35	3.00	0.81	19.42	0.107
Sex	Female vs male	35	3.42	0.53	12.88	0.167
LDH	Elevated vs normal	32	1.72	0.57	4.97	0.324
WBC count	Elevated vs normal	32	1.32	0.36	4.06	0.649
Stage	III and IV vs I and II	32	0.34	0.07	2.37	0.237
Bone marrow involvement	Present vs absent	35	1.21	0.40	3.51	0.720
Ki-67 positivity	High vs low	19	1.17	0.19	8.91	0.863
IPI	High risk vs other	32	0.49	0.03	2.55	0.450
MIPI	Other vs low risk	31	1.38	0.35	9.04	0.674
MIPI	High risk vs other	31	1.12	0.29	3.73	0.857
Treatment	Other vs hyper-CVAD/MA	35	6.18	1.64	40.21	0.005

RR: Relative risk; LCL: Lower confidence limit; UCL: Upper confidence limit; IPI: International prognostic index; MIPI: Mantle cell lymphoma international prognostic index; WBC: White blood cell; LDH: Lactate dehydrogenase.

Table 4 Prognostic relevance of event-free survival according to the univariate Cox regression

Prognostic factor	Comparison	n	RR	95% LCL	95% UCL	P
Age (yr)	≥ 60 vs < 60	35	5.27	1.47	33.77	0.007
Sex	Female vs male	35	2.67	0.61	8.39	0.170
LDH	Elevated vs normal	32	1.64	0.67	3.88	0.274
WBC count	Elevated vs normal	32	1.53	0.57	3.76	0.377
Stage	III and IV vs I and II	32	0.83	0.27	3.60	0.772
Bone marrow involvement	Present vs absent	35	1.24	0.49	2.95	0.639
Ki-67 positivity	High vs low	19	0.62	0.16	2.19	0.459
IPI	High risk vs other	32	1.07	0.25	3.24	0.918
MIPI	Other vs low risk	31	2.54	0.72	16.09	0.164
MIPI	High risk vs other	31	0.75	0.24	1.98	0.580
Treatment	Other vs hyper-CVAD/MA	35	2.81	1.02	9.25	0.044

RR: Relative risk; LCL: Lower confidence limit; UCL: Upper confidence limit; IPI: International prognostic index; MIPI: Mantle cell lymphoma international prognostic index; WBC: White blood cell; LDH: Lactate dehydrogenase.

Table 5 Prognostic relevance of event-free survival according to the multiple Cox regression

Prognostic factor	Comparison	RR	95% LCL	95% UCL	P
Age (yr)	≥ 60 vs < 60	4.17	0.95	29.25	0.059
Treatment	Other vs hyper-CVAD/MA	1.51	0.52	5.5	0.474

RR: Relative risk; LCL: Lower confidence limit; UCL: Upper confidence limit.